JMP Securities Downgrades Edge Therapeutics (EDGE) to Market Perform, 'Phase 3 NEWTON 2 trial failed to showbenefit with EG-1962' Mar 28, 2018 11:12AM
Edge Therapeutics to Participate in the JMP Securities Life Science Conference Jun 15, 2017 07:00AM
Edge Therapeutics to Present at Upcoming Investor Conferences Jun 2, 2016 07:30AM
JMP Securities Starts Edge Therapeutics (EDGE) at Market Outperform Oct 26, 2015 08:10AM
Edge Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Oct 6, 2015 04:05PM


Oct 1, 2015 11:16AM Edge Therapeutics (EDGE) IPO Opens Modestly Higher
Oct 1, 2015 09:42AM Edge Therapeutics (EDGE) IPO Prices at $11, Well Below Expected Range
Sep 30, 2015 08:34PM Edge Therapeutics Announces Pricing of Its Initial Public Offering